IDH1 and central nervous system cancer: Generally speaking, glioma patients with the IDH1 mutation have a more favorable prognosis, and the mutation is frequently expressed in patients with an LGG but rarely detected in patients with a WHO grade 4 glioma (Ceccarelli et al., 2016).